Executive SummaryCentocor files PLA for the cardiac imaging agent March 31. Centocor said that clinical studies have been conducted in about 1,000 patients during the past three and one-half years. Potential indications include detection of post-heart attack cardiac damage, diagnosing myocarditus and diagnosing heart transplant rejection.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.